Pharmacopeia
METOCLOPRAMIDE
Core pharmacology
- Class Group
Anti-emetic
Dopamine Antagonist
- Indications Uses
1. Prokinetic
2. Antiemetic
3. Migraine
4. Reflux oesophagitis- Presentation
PO/IV
- Physiological effects
CVS: Hypotension after IV; Dysrhythmias and QTc
GIT
1. Selective stimulation of gastric muscarinic receptors
- Coordinated GIT contraction (accelerates gastric emptying)
- Increased amplitude and frequency of Longitudinal muscle contraction
- Lowers threshold for peristaltic reflex to occur
2. Direct action on smooth muscle to increase tone (including increased LOS)
3. Reduces intestinal muscle fatigueCNS
- Neuroleptic effects
- Extrapyramidal effects
- Increase prolactinGU- Increased uterine peristalsis
- Protein binding
20% PB
- Introduction
Antiemetic and prokinetic dopamine D2 antagonist.
- Mechanism of action
Peripheral D2 antagonism, augmentation of peripheral cholinergic responses and direct smooth-muscle effects increase gastrointestinal motility. Central D2 blockade raises the vomiting threshold at the chemoreceptor trigger zone, and reduced visceral afferent input contributes to antiemesis.
- Adverse Effects Toxicity
Drowsiness, dizziness and faintness. Bowel disturbance. Extrapyramidal reactions including akathisia and oculogyric crises. Neuroleptic malignant syndrome. Hyperprolactinaemia.
- Absorption
Rapid oral absorption. Oral bioavailability 32-97% because of first-pass sulfate conjugation.
- Volume of distribution
2.2-3.4 L/kg.
- Metabolism
Primarily hepatic metabolism. The major metabolite is a sulfate derivative.
- Excretion
80% of an oral dose is excreted in urine within 24 hours. 20% of the urinary amount is unchanged, with the remainder as conjugated parent drug or metabolites.
- Half-life
2.6-5 hours.